More Former Merck-ers, From Keytruda® Development Team -- Taking On New Research & Development Roles...

While this life science maven has added her skills to the boards and executive suites of two other companies, here post-Merck, her current engagement is the most clearly applicable one -- for her power-alley skill-set. She will do great things, at Karyopharm Therapeutics, Condor predicts.

Here's that story, from FiercePharma:

. . .Karyopharm Therapeutics is hoping a bit of Keytruda stardust may wear off on the cancer-focused biotech with the addition of a former Merck & Co. executive as chief medical officer.

Reshma Rangwala, M.D., Ph.D., takes on the new role in mid-April and will be responsible for leading Karyopharm’s clinical development programs and strategy, according to a Tuesday announcement from the Newton, Massachusetts, company.

Rangwala was previously executive clinical director at Merck, where she was involved in the clinical development of the blockbuster immunotherapy Keytruda. After working at Merck, Rangwala served as Genmab’s medical VP and, most recently, led the clinical development of batiraxcept across multiple tumor types as Aravive’s chief medical officer. . . .

And so, indeed -- Mr. Dylan was right: ". . .The times, they are a-changin'. . ." -- here's to a hope for peace, in Ukraine. Smile. . . .

नमस्ते